Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.
Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, Godwin A, Moslehi R, Olipade O, Brunet JS, Stickeler E, Kieback DG, Kreienberg R, Weber B, Narod SA, Runnebaum IB. Wang-Gohrke S, et al. Among authors: lerman c. Br J Cancer. 1999 Sep;81(1):179-83. doi: 10.1038/sj.bjc.6690669. Br J Cancer. 1999. PMID: 10487631 Free PMC article.
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.
Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, Garber J, Lerman C, Olopade OI, Foulkes WD, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dubé MP, Kieback DG, Narod SA. Runnebaum IB, et al. Among authors: lerman c. Pharmacogenetics. 2001 Oct;11(7):635-8. doi: 10.1097/00008571-200110000-00010. Pharmacogenetics. 2001. PMID: 11668223
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes.
Brunet JS, Ghadirian P, Rebbeck TR, Lerman C, Garber JE, Tonin PN, Abrahamson J, Foulkes WD, Daly M, Wagner-Costalas J, Godwin A, Olopade OI, Moslehi R, Liede A, Futreal PA, Weber BL, Lenoir GM, Lynch HT, Narod SA. Brunet JS, et al. Among authors: lerman c. J Natl Cancer Inst. 1998 May 20;90(10):761-6. doi: 10.1093/jnci/90.10.761. J Natl Cancer Inst. 1998. PMID: 9605646
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2.
Jernström H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod SA. Jernström H, et al. Among authors: lerman c. Lancet. 1999 Nov 27;354(9193):1846-50. doi: 10.1016/s0140-6736(99)04336-6. Lancet. 1999. PMID: 10584720 Free article.
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H; Hereditary Breast Cancer Clinical Study Group. Narod SA, et al. Among authors: lerman c. Lancet. 2000 Dec 2;356(9245):1876-81. doi: 10.1016/s0140-6736(00)03258-x. Lancet. 2000. PMID: 11130383
A descriptive study of BRCA1 testing and reactions to disclosure of test results.
Lynch HT, Lemon SJ, Durham C, Tinley ST, Connolly C, Lynch JF, Surdam J, Orinion E, Slominski-Caster S, Watson P, Lerman C, Tonin P, Lenoir G, Serova O, Narod S. Lynch HT, et al. Among authors: lerman c. Cancer. 1997 Jun 1;79(11):2219-28. doi: 10.1002/(sici)1097-0142(19970601)79:11<2219::aid-cncr21>3.0.co;2-y. Cancer. 1997. PMID: 9179070
433 results